Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

Aziz Farhat MD

doi:10.1002/cncr.70568

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

2026-08-13

0

OA

AI

A

Aziz Farhat MD

G

Georgina El Hajjar MD

H

Hagop M. Kantarjian

K

Koji Sasaki

N

Nicholas J. Short

B

Branko Cuglievan MD

S

Sanam Loghavi MD

K

Keyur Patel MD, PhD

Á

Álex Bataller

W

Wei Ying Jen MA, BMBCh, MRCP, MMed, FRCPath

M

Musa Yilmaz MD

G

Guillermo Montalban‐Bravo

D

Danielle Hammond MD

N

Naveen Pemmaraju

N

Naval Daver

F

Farhad Ravandi MD

E

Elias Jabbour

T

Tapan M. Kadia

G

Gautam Borthakur MD

G

Guillermo Garcia‐Manero

C

Courtney D. DiNardo

G

Ghayas C. Issa MD, MS *

DOI：10.1002/cncr.70568

Original

Save

View PDF

Abstract

En 中文

Nucleophosmin 1-mutated (NPM1mt) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long-term outcomes remain suboptimal without clear predictors identified by therapy.

Keywords:

acute

azacitidine

cladribine

cytarabine

leukemia

mutation

myeloid

nucleophosmin

prognosis

retrospective studies

venetoclax

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

Abstract

AI Summary

Journal

Organization

Cited Papers

Citing Papers